Marksans Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE750C01026
  • NSEID: MARKSANS
  • BSEID: 524404
INR
290.90
-8.25 (-2.76%)
BSENSE

Nov 20

BSE+NSE Vol: 9.82 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 604869,
    "name": "Marksans Pharma",
    "stock_name": "Marksans Pharma",
    "full_name": "Marksans Pharma Ltd",
    "name_url": "stocks-analysis/marksans-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "290.90",
    "chg": -8.25,
    "chgp": "-2.76%",
    "dir": -1,
    "prev_price": "299.15",
    "mcapval": "13,304.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524404,
    "symbol": "MARKSANS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE750C01026",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "9.82 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/marksans-pharma-604869-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Marksans Pharma Falls 8.67%: Valuation and Technical Shifts Define the Week",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/marksans-pharma-falls-867-valuation-and-technical-shifts-define-the-week-4270731",
        "imagepath": "",
        "date": "2026-11-21 17:00:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Nov:</strong> Upgrade to Buy on strong financials and bullish technicals</p>\n                    <p><strong>16 Nov:</strong> Technical momentum shifts signal bullish outlook</p>\n                    <p><strong>19 Nov:</strong> Downgrade to Hold amid mixed technicals and expensive valuation</p>\n                    <p><strong>19 Nov:</strong> Valuation shifts reflect changing market sentiment</p>\n                    <p><strong>20 Nov:</strong> Week closes at Rs.290.90 (-8.67%) vs Sensex +1.55%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\">\n                        <div class=\"stat-label\">Week Open</div>\n              ..."
      },
      {
        "title": "Marksans Pharma Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/marksans-pharma-ltd-valuation-shifts-signal-changing-market-sentiment-4267378",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MarksansPharmaL_valuationdot_4267378.png",
        "date": "2026-11-19 08:00:32",
        "description": "Marksans Pharma Ltd has seen its valuation grade revised from very expensive to expensive, reflecting a notable shift in price attractiveness despite robust long-term returns. The pharmaceutical company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios indicate a premium valuation relative to historical averages and peer benchmarks, prompting a reassessment of its investment appeal."
      },
      {
        "title": "Marksans Pharma Upgraded to Buy on Strong Financials and Bullish Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/marksans-pharma-upgraded-to-buy-on-strong-financials-and-bullish-technicals-4263252",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MarksansPharmaL_mojoScore_4263252.png",
        "date": "2026-11-16 08:35:16",
        "description": "Marksans Pharma Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. This upgrade, announced on 13 Nov 2026, comes amid robust quarterly results, a bullish technical outlook, and sustained long-term outperformance relative to the broader market."
      },
      {
        "title": "Marksans Pharma Ltd Technical Momentum Shifts Signal Bullish Outlook",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/marksans-pharma-ltd-technical-momentum-shifts-signal-bullish-outlook-4263035",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MarksansPharmaL_technicaldot_4263035.png",
        "date": "2026-11-16 08:02:18",
        "description": "Marksans Pharma Ltd has recently experienced a notable shift in its technical momentum, with key indicators signalling an upgrade from a mildly bullish to a bullish trend. This change, coupled with a strong fundamental backdrop and impressive long-term returns, positions the small-cap pharmaceutical company favourably amid a volatile market environment."
      },
      {
        "title": "Marksans Pharma Ltd is Rated Buy",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/marksans-pharma-ltd-is-rated-buy-4262411",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MarksansPharmaL_mojoScore_4262411.png",
        "date": "2026-11-15 10:10:29",
        "description": "Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 13 November 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 November 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "Marksans Pharma Ltd Reports Positive Quarterly Performance Amid Margin Expansion",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/marksans-pharma-ltd-reports-positive-quarterly-performance-amid-margin-expansion-4251106",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MarksansPharmaL_fintrenddot_4251106.png",
        "date": "2026-11-05 08:00:29",
        "description": "Marksans Pharma Ltd has delivered a robust quarterly performance for September 2026, registering record net sales and profit before depreciation, interest and taxes (PBDIT), alongside a significant rise in profit after tax (PAT). Despite a recent downgrade in its Mojo Grade from Buy to Hold, the company’s financial trajectory remains positive, reflecting strong operational execution amid evolving margin dynamics."
      },
      {
        "title": "Marksans Pharma Ltd is Rated Buy by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/marksans-pharma-ltd-is-rated-buy-by-marketsmojo-4250451",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/MarksansPharmaL_mojoScore_4250451.png",
        "date": "2026-11-04 10:11:29",
        "description": "Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 November 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Marksans Pharma Ltd is Rated Buy by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/marksans-pharma-ltd-is-rated-buy-by-marketsmojo-4236762",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/MarksansPharmaL_mojoScore_4236762.png",
        "date": "2026-10-24 10:10:39",
        "description": "Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 October 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Marksans Pharma Ltd is Rated Buy",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/marksans-pharma-ltd-is-rated-buy-4224117",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/MarksansPharmaL_mojoScore_4224117.png",
        "date": "2026-10-13 10:10:56",
        "description": "Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 October 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      }
    ],
    "total": 92,
    "sid": "604869",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/marksans-pharma-604869"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "13-Nov-2026",
      "details": "Transcript of Investors/Analyst meet on Q2 FY27 Financial Results",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "05-Nov-2026",
      "details": "Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "05-Nov-2026",
      "details": "Newspaper Publication for Unaudited Financial Results for the quarter and half year ended September 30 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Marksans Pharma Ltd has declared <strong>90%</strong> dividend, ex-date: 20 Aug 26",
          "dt": "2026-08-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Marksans Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08",
          "dt": "2008-03-11",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

13-Nov-2026 | Source : BSE

Transcript of Investors/Analyst meet on Q2 FY27 Financial Results

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

05-Nov-2026 | Source : BSE

Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results

Announcement under Regulation 30 (LODR)-Newspaper Publication

05-Nov-2026 | Source : BSE

Newspaper Publication for Unaudited Financial Results for the quarter and half year ended September 30 2026

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Marksans Pharma Ltd has declared 90% dividend, ex-date: 20 Aug 26

stock-summary
SPLITS

Marksans Pharma Ltd has announced 1:10 stock split, ex-date: 11 Mar 08

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available